| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 158 | 2025 | 665 | 24.120 |
Why?
|
| Aged | 231 | 2025 | 13339 | 6.130 |
Why?
|
| Pain | 25 | 2024 | 406 | 5.900 |
Why?
|
| Pain Management | 16 | 2024 | 145 | 5.850 |
Why?
|
| Osteoarthritis, Knee | 22 | 2021 | 383 | 5.810 |
Why?
|
| Homes for the Aged | 29 | 2024 | 164 | 5.710 |
Why?
|
| United States | 161 | 2024 | 7510 | 5.580 |
Why?
|
| Dementia | 25 | 2024 | 247 | 5.490 |
Why?
|
| Cognitive Dysfunction | 15 | 2024 | 262 | 5.150 |
Why?
|
| Humans | 398 | 2025 | 59491 | 5.070 |
Why?
|
| Aged, 80 and over | 133 | 2025 | 5089 | 5.040 |
Why?
|
| Female | 282 | 2025 | 30906 | 4.700 |
Why?
|
| Male | 256 | 2025 | 27559 | 4.690 |
Why?
|
| Cross-Sectional Studies | 87 | 2024 | 2468 | 4.550 |
Why?
|
| Drug Utilization | 35 | 2021 | 223 | 4.470 |
Why?
|
| Analgesics, Opioid | 16 | 2024 | 496 | 4.030 |
Why?
|
| Medicare | 34 | 2024 | 601 | 3.980 |
Why?
|
| Antipsychotic Agents | 24 | 2024 | 312 | 3.910 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2021 | 212 | 3.810 |
Why?
|
| Depression | 24 | 2024 | 857 | 3.740 |
Why?
|
| Long-Term Care | 29 | 2023 | 174 | 3.460 |
Why?
|
| Frailty | 12 | 2024 | 125 | 3.400 |
Why?
|
| Practice Patterns, Physicians' | 20 | 2021 | 714 | 3.380 |
Why?
|
| Skilled Nursing Facilities | 12 | 2023 | 84 | 3.370 |
Why?
|
| Drug Prescriptions | 18 | 2021 | 188 | 3.220 |
Why?
|
| Pain Measurement | 23 | 2021 | 330 | 3.140 |
Why?
|
| Analgesics | 15 | 2021 | 100 | 3.050 |
Why?
|
| Spondylarthritis | 8 | 2023 | 42 | 3.010 |
Why?
|
| Activities of Daily Living | 21 | 2023 | 298 | 3.000 |
Why?
|
| Drug Utilization Review | 14 | 2020 | 56 | 2.920 |
Why?
|
| Alzheimer Disease | 19 | 2024 | 550 | 2.920 |
Why?
|
| Middle Aged | 126 | 2025 | 16274 | 2.760 |
Why?
|
| Chronic Pain | 7 | 2024 | 142 | 2.680 |
Why?
|
| Quality of Life | 14 | 2023 | 1116 | 2.660 |
Why?
|
| Feeding and Eating Disorders | 6 | 2023 | 47 | 2.610 |
Why?
|
| Sexual Partners | 6 | 2015 | 74 | 2.540 |
Why?
|
| Adult | 110 | 2024 | 15782 | 2.430 |
Why?
|
| Heart Failure | 11 | 2023 | 866 | 2.310 |
Why?
|
| Prevalence | 41 | 2023 | 1281 | 2.310 |
Why?
|
| Hospitalization | 25 | 2023 | 1282 | 2.270 |
Why?
|
| Mental Disorders | 6 | 2023 | 764 | 2.090 |
Why?
|
| Frail Elderly | 16 | 2024 | 110 | 2.060 |
Why?
|
| Logistic Models | 41 | 2022 | 1252 | 2.040 |
Why?
|
| Citalopram | 4 | 2016 | 17 | 2.030 |
Why?
|
| Severity of Illness Index | 22 | 2021 | 1449 | 1.980 |
Why?
|
| Knee Joint | 12 | 2021 | 284 | 1.940 |
Why?
|
| Cancer Pain | 3 | 2020 | 13 | 1.920 |
Why?
|
| Retrospective Studies | 61 | 2025 | 6007 | 1.920 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2017 | 149 | 1.890 |
Why?
|
| Atrial Fibrillation | 7 | 2024 | 798 | 1.860 |
Why?
|
| Age Factors | 30 | 2022 | 1518 | 1.800 |
Why?
|
| Obesity | 10 | 2020 | 1186 | 1.800 |
Why?
|
| Young Adult | 34 | 2024 | 4329 | 1.760 |
Why?
|
| Fractures, Bone | 5 | 2018 | 139 | 1.750 |
Why?
|
| Cholinesterase Inhibitors | 8 | 2024 | 45 | 1.730 |
Why?
|
| Contraception Behavior | 5 | 2012 | 35 | 1.720 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2024 | 202 | 1.720 |
Why?
|
| Stroke | 13 | 2023 | 1138 | 1.710 |
Why?
|
| Models, Statistical | 7 | 2019 | 306 | 1.710 |
Why?
|
| Mental Health Services | 3 | 2022 | 299 | 1.700 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2023 | 566 | 1.690 |
Why?
|
| Complementary Therapies | 5 | 2013 | 60 | 1.690 |
Why?
|
| Risk Factors | 67 | 2023 | 5015 | 1.680 |
Why?
|
| Hyaluronic Acid | 3 | 2018 | 63 | 1.660 |
Why?
|
| Socioeconomic Factors | 24 | 2021 | 781 | 1.620 |
Why?
|
| Bulimia | 3 | 2022 | 15 | 1.610 |
Why?
|
| Attitude of Health Personnel | 7 | 2011 | 558 | 1.610 |
Why?
|
| Adolescent | 43 | 2024 | 5930 | 1.570 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 254 | 1.570 |
Why?
|
| Pharmacists | 6 | 2011 | 123 | 1.560 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2016 | 28 | 1.520 |
Why?
|
| Liver Cirrhosis | 4 | 2013 | 160 | 1.510 |
Why?
|
| Behavioral Symptoms | 3 | 2021 | 15 | 1.490 |
Why?
|
| Sexual Behavior | 6 | 2021 | 183 | 1.490 |
Why?
|
| Electronic Prescribing | 4 | 2012 | 11 | 1.490 |
Why?
|
| Cohort Studies | 33 | 2024 | 2442 | 1.470 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2017 | 34 | 1.450 |
Why?
|
| Sulfonylurea Compounds | 3 | 2015 | 14 | 1.420 |
Why?
|
| Social Participation | 3 | 2025 | 16 | 1.410 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 265 | 1.390 |
Why?
|
| Osteoarthritis | 3 | 2016 | 129 | 1.380 |
Why?
|
| Mass Screening | 6 | 2021 | 647 | 1.380 |
Why?
|
| Odds Ratio | 24 | 2022 | 773 | 1.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2021 | 674 | 1.350 |
Why?
|
| Pharmaceutical Services | 6 | 2011 | 31 | 1.330 |
Why?
|
| Anticoagulants | 10 | 2024 | 487 | 1.320 |
Why?
|
| Risk-Taking | 8 | 2015 | 160 | 1.300 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 446 | 1.290 |
Why?
|
| Exercise | 9 | 2020 | 916 | 1.290 |
Why?
|
| Behavioral Risk Factor Surveillance System | 7 | 2024 | 48 | 1.270 |
Why?
|
| Hypoglycemic Agents | 6 | 2015 | 212 | 1.260 |
Why?
|
| Geriatric Assessment | 15 | 2023 | 161 | 1.240 |
Why?
|
| Quality Assurance, Health Care | 6 | 2015 | 246 | 1.230 |
Why?
|
| Neuralgia | 2 | 2021 | 20 | 1.210 |
Why?
|
| Comorbidity | 23 | 2022 | 1090 | 1.210 |
Why?
|
| Cross Infection | 4 | 2015 | 151 | 1.200 |
Why?
|
| Tryptamines | 3 | 2016 | 12 | 1.180 |
Why?
|
| Psychotropic Drugs | 6 | 2015 | 83 | 1.180 |
Why?
|
| Viscosupplements | 2 | 2018 | 13 | 1.170 |
Why?
|
| Accidental Falls | 7 | 2018 | 145 | 1.170 |
Why?
|
| Neoplasms | 5 | 2020 | 1242 | 1.170 |
Why?
|
| Ambulatory Care | 5 | 2022 | 300 | 1.160 |
Why?
|
| Pregnancy Complications | 6 | 2020 | 391 | 1.150 |
Why?
|
| Health Behavior | 8 | 2012 | 473 | 1.140 |
Why?
|
| Clostridium Infections | 3 | 2012 | 46 | 1.140 |
Why?
|
| Memantine | 2 | 2024 | 23 | 1.130 |
Why?
|
| Psychiatry | 2 | 2023 | 129 | 1.110 |
Why?
|
| Pregnancy, Unwanted | 3 | 2012 | 10 | 1.110 |
Why?
|
| Chondroitin | 3 | 2015 | 9 | 1.100 |
Why?
|
| Mammography | 3 | 2019 | 272 | 1.100 |
Why?
|
| Glucosamine | 3 | 2015 | 31 | 1.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2017 | 164 | 1.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2017 | 142 | 1.070 |
Why?
|
| Physicians | 4 | 2021 | 436 | 1.060 |
Why?
|
| Caregivers | 2 | 2024 | 216 | 1.060 |
Why?
|
| Back Pain | 4 | 2022 | 51 | 1.050 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 153 | 1.050 |
Why?
|
| Depressive Disorder | 5 | 2018 | 293 | 1.050 |
Why?
|
| Migraine Disorders | 3 | 2016 | 45 | 1.040 |
Why?
|
| Antidepressive Agents | 13 | 2020 | 229 | 1.030 |
Why?
|
| Biomedical Research | 3 | 2021 | 250 | 1.030 |
Why?
|
| Proportional Hazards Models | 18 | 2020 | 673 | 1.020 |
Why?
|
| Surveys and Questionnaires | 19 | 2024 | 2592 | 1.020 |
Why?
|
| Hospice Care | 5 | 2023 | 59 | 1.020 |
Why?
|
| Brain Injuries | 5 | 2014 | 140 | 1.010 |
Why?
|
| Racism | 2 | 2020 | 81 | 1.010 |
Why?
|
| Contraceptive Agents, Female | 3 | 2012 | 24 | 1.000 |
Why?
|
| Pharmacoepidemiology | 2 | 2016 | 11 | 1.000 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2023 | 126 | 1.000 |
Why?
|
| Qualitative Research | 8 | 2024 | 609 | 0.980 |
Why?
|
| Bias | 6 | 2019 | 106 | 0.970 |
Why?
|
| Aging | 4 | 2020 | 723 | 0.970 |
Why?
|
| Skin Ulcer | 1 | 2025 | 14 | 0.970 |
Why?
|
| Longitudinal Studies | 14 | 2024 | 1225 | 0.960 |
Why?
|
| Pharmaceutical Preparations | 5 | 2021 | 122 | 0.960 |
Why?
|
| Coitus | 3 | 2015 | 15 | 0.960 |
Why?
|
| Computer Simulation | 2 | 2019 | 455 | 0.950 |
Why?
|
| Treatment Outcome | 19 | 2024 | 5183 | 0.930 |
Why?
|
| Pandemics | 3 | 2023 | 608 | 0.930 |
Why?
|
| Anticonvulsants | 3 | 2020 | 95 | 0.920 |
Why?
|
| Practice Guidelines as Topic | 8 | 2019 | 703 | 0.920 |
Why?
|
| Delirium | 2 | 2023 | 56 | 0.920 |
Why?
|
| Databases, Factual | 22 | 2024 | 838 | 0.910 |
Why?
|
| Oxycodone | 4 | 2018 | 32 | 0.900 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2024 | 741 | 0.900 |
Why?
|
| Binge-Eating Disorder | 2 | 2022 | 11 | 0.900 |
Why?
|
| Vision Disorders | 1 | 2024 | 59 | 0.880 |
Why?
|
| Depressive Disorder, Major | 3 | 2016 | 258 | 0.870 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 11 | 0.860 |
Why?
|
| Deprescriptions | 2 | 2020 | 22 | 0.860 |
Why?
|
| Occult Blood | 1 | 2023 | 15 | 0.850 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 72 | 0.850 |
Why?
|
| Symptom Assessment | 2 | 2020 | 39 | 0.850 |
Why?
|
| Warfarin | 5 | 2020 | 109 | 0.840 |
Why?
|
| Self Report | 6 | 2019 | 366 | 0.840 |
Why?
|
| Transition to Adult Care | 1 | 2023 | 8 | 0.840 |
Why?
|
| Quality of Health Care | 10 | 2020 | 519 | 0.830 |
Why?
|
| Dietary Supplements | 2 | 2015 | 247 | 0.820 |
Why?
|
| Gender Identity | 3 | 2023 | 61 | 0.820 |
Why?
|
| Poverty | 2 | 2017 | 286 | 0.820 |
Why?
|
| Chronic Disease | 9 | 2024 | 735 | 0.810 |
Why?
|
| Cognition | 14 | 2023 | 459 | 0.810 |
Why?
|
| Hip Fractures | 3 | 2015 | 79 | 0.810 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.800 |
Why?
|
| Reproducibility of Results | 10 | 2022 | 1551 | 0.800 |
Why?
|
| Polypharmacy | 6 | 2020 | 62 | 0.800 |
Why?
|
| Loneliness | 1 | 2022 | 18 | 0.800 |
Why?
|
| Diabetes Mellitus | 6 | 2023 | 537 | 0.790 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 39 | 0.790 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2023 | 66 | 0.790 |
Why?
|
| Substance-Related Disorders | 5 | 2022 | 691 | 0.780 |
Why?
|
| Prescription Drug Misuse | 1 | 2022 | 22 | 0.780 |
Why?
|
| Body Mass Index | 12 | 2021 | 886 | 0.770 |
Why?
|
| Incidence | 12 | 2020 | 1237 | 0.760 |
Why?
|
| Health Surveys | 6 | 2016 | 306 | 0.760 |
Why?
|
| Radiography | 9 | 2017 | 506 | 0.760 |
Why?
|
| Geography, Medical | 1 | 2021 | 5 | 0.750 |
Why?
|
| Guideline Adherence | 5 | 2014 | 296 | 0.750 |
Why?
|
| Propensity Score | 3 | 2019 | 134 | 0.750 |
Why?
|
| Insurance, Health | 1 | 2022 | 141 | 0.740 |
Why?
|
| Medicare Part D | 5 | 2020 | 35 | 0.740 |
Why?
|
| Confidence Intervals | 14 | 2015 | 256 | 0.740 |
Why?
|
| Multiple Sclerosis | 2 | 2014 | 208 | 0.730 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 72 | 0.730 |
Why?
|
| Glucocorticoids | 3 | 2020 | 171 | 0.730 |
Why?
|
| Sex Factors | 22 | 2024 | 960 | 0.730 |
Why?
|
| Medication Errors | 5 | 2012 | 116 | 0.720 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 141 | 0.720 |
Why?
|
| Medical Order Entry Systems | 4 | 2010 | 45 | 0.720 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 16 | 0.720 |
Why?
|
| Tooth Loss | 1 | 2020 | 8 | 0.710 |
Why?
|
| Prospective Payment System | 4 | 2006 | 8 | 0.710 |
Why?
|
| Marijuana Abuse | 1 | 2020 | 20 | 0.710 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2019 | 668 | 0.710 |
Why?
|
| Clinical Pharmacy Information Systems | 2 | 2012 | 9 | 0.710 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 124 | 0.700 |
Why?
|
| Overweight | 3 | 2013 | 247 | 0.700 |
Why?
|
| Stroke Volume | 2 | 2023 | 317 | 0.700 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 1 | 2020 | 6 | 0.700 |
Why?
|
| Social Segregation | 1 | 2020 | 10 | 0.700 |
Why?
|
| Off-Label Use | 3 | 2018 | 15 | 0.690 |
Why?
|
| Social Discrimination | 1 | 2020 | 15 | 0.690 |
Why?
|
| Disease Progression | 10 | 2023 | 1044 | 0.690 |
Why?
|
| Arthroplasty, Replacement | 1 | 2020 | 15 | 0.690 |
Why?
|
| Body Weight | 5 | 2020 | 378 | 0.690 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 77 | 0.690 |
Why?
|
| Inappropriate Prescribing | 3 | 2020 | 67 | 0.680 |
Why?
|
| Pregnancy | 15 | 2023 | 2355 | 0.670 |
Why?
|
| Minority Groups | 4 | 2019 | 140 | 0.670 |
Why?
|
| Sex Distribution | 11 | 2019 | 254 | 0.670 |
Why?
|
| Cannabis | 1 | 2020 | 47 | 0.670 |
Why?
|
| Social Support | 2 | 2023 | 358 | 0.660 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2019 | 7 | 0.660 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 330 | 0.660 |
Why?
|
| Disabled Persons | 1 | 2022 | 205 | 0.660 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 196 | 0.650 |
Why?
|
| Social Isolation | 3 | 2024 | 28 | 0.650 |
Why?
|
| Myocardial Infarction | 8 | 2018 | 864 | 0.640 |
Why?
|
| Prospective Studies | 16 | 2022 | 3101 | 0.630 |
Why?
|
| Rivaroxaban | 1 | 2018 | 21 | 0.630 |
Why?
|
| Geographic Mapping | 1 | 2018 | 6 | 0.630 |
Why?
|
| Education, Medical | 1 | 2021 | 175 | 0.630 |
Why?
|
| Dabigatran | 1 | 2018 | 23 | 0.630 |
Why?
|
| Epilepsy | 1 | 2020 | 108 | 0.630 |
Why?
|
| Professional Role | 3 | 2007 | 37 | 0.620 |
Why?
|
| Health Status Disparities | 4 | 2024 | 147 | 0.620 |
Why?
|
| Consultants | 3 | 2006 | 12 | 0.620 |
Why?
|
| Residence Characteristics | 3 | 2020 | 224 | 0.620 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2015 | 47 | 0.610 |
Why?
|
| Patient Discharge | 9 | 2022 | 479 | 0.610 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 158 | 0.610 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 119 | 0.610 |
Why?
|
| Electronic Health Records | 4 | 2021 | 352 | 0.610 |
Why?
|
| Unemployment | 1 | 2018 | 17 | 0.600 |
Why?
|
| Antihypertensive Agents | 6 | 2010 | 172 | 0.600 |
Why?
|
| Research Design | 6 | 2017 | 565 | 0.590 |
Why?
|
| Comparative Effectiveness Research | 2 | 2024 | 46 | 0.590 |
Why?
|
| Gastrointestinal Diseases | 2 | 2013 | 73 | 0.590 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 11 | 0.580 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.580 |
Why?
|
| Job Satisfaction | 3 | 2010 | 134 | 0.580 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 33 | 0.580 |
Why?
|
| Students | 2 | 2019 | 207 | 0.580 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2017 | 63 | 0.580 |
Why?
|
| Health Services Misuse | 1 | 2017 | 19 | 0.570 |
Why?
|
| Child | 11 | 2024 | 4304 | 0.570 |
Why?
|
| Data Collection | 7 | 2010 | 384 | 0.570 |
Why?
|
| Alcohol Drinking | 4 | 2008 | 299 | 0.570 |
Why?
|
| Models, Theoretical | 5 | 2013 | 258 | 0.570 |
Why?
|
| Case-Control Studies | 18 | 2018 | 1063 | 0.560 |
Why?
|
| Food Supply | 1 | 2017 | 72 | 0.560 |
Why?
|
| Criminal Law | 1 | 2018 | 91 | 0.560 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 45 | 0.560 |
Why?
|
| Time Factors | 20 | 2024 | 3579 | 0.550 |
Why?
|
| Parkinson Disease | 4 | 2002 | 97 | 0.550 |
Why?
|
| Curriculum | 1 | 2021 | 550 | 0.550 |
Why?
|
| Nursing Staff | 2 | 2007 | 41 | 0.550 |
Why?
|
| Drug Therapy | 2 | 2007 | 61 | 0.540 |
Why?
|
| Indans | 3 | 2005 | 11 | 0.540 |
Why?
|
| Ontario | 8 | 2021 | 43 | 0.540 |
Why?
|
| Causality | 1 | 2016 | 56 | 0.530 |
Why?
|
| Alcoholism | 2 | 2018 | 307 | 0.530 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 36 | 0.530 |
Why?
|
| Safety | 2 | 2007 | 141 | 0.530 |
Why?
|
| Population Surveillance | 8 | 2013 | 205 | 0.530 |
Why?
|
| Morphine | 1 | 2016 | 52 | 0.530 |
Why?
|
| Algorithms | 7 | 2022 | 989 | 0.520 |
Why?
|
| Piperidines | 3 | 2005 | 50 | 0.520 |
Why?
|
| Cardiovascular Diseases | 15 | 2020 | 827 | 0.520 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 2329 | 0.520 |
Why?
|
| Child Behavior | 1 | 2016 | 69 | 0.520 |
Why?
|
| Urban Population | 2 | 2015 | 182 | 0.520 |
Why?
|
| Actigraphy | 1 | 2016 | 47 | 0.510 |
Why?
|
| Risk Assessment | 15 | 2017 | 1914 | 0.510 |
Why?
|
| Fentanyl | 1 | 2016 | 70 | 0.510 |
Why?
|
| Age Distribution | 9 | 2017 | 261 | 0.510 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 16 | 0.510 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 79 | 0.510 |
Why?
|
| Patient Compliance | 4 | 2014 | 372 | 0.510 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 542 | 0.510 |
Why?
|
| Cognition Disorders | 12 | 2021 | 218 | 0.500 |
Why?
|
| Medication Adherence | 3 | 2015 | 255 | 0.500 |
Why?
|
| Software | 2 | 2010 | 367 | 0.500 |
Why?
|
| Dyslipidemias | 1 | 2015 | 34 | 0.500 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 34 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 3 | 2012 | 724 | 0.500 |
Why?
|
| Selection Bias | 2 | 2016 | 24 | 0.500 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2015 | 35 | 0.490 |
Why?
|
| Abdominal Pain | 1 | 2015 | 92 | 0.490 |
Why?
|
| Mortality | 2 | 2019 | 159 | 0.490 |
Why?
|
| Brain Ischemia | 1 | 2019 | 403 | 0.480 |
Why?
|
| Violence | 3 | 2013 | 149 | 0.470 |
Why?
|
| Smoking | 9 | 2015 | 830 | 0.470 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2012 | 71 | 0.470 |
Why?
|
| Inflammation | 1 | 2021 | 1102 | 0.470 |
Why?
|
| Psychotic Disorders | 3 | 2021 | 151 | 0.470 |
Why?
|
| Medicaid | 13 | 2021 | 335 | 0.470 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 87 | 0.460 |
Why?
|
| Heterosexuality | 1 | 2014 | 9 | 0.460 |
Why?
|
| Contraception | 2 | 2012 | 64 | 0.460 |
Why?
|
| Documentation | 2 | 2014 | 129 | 0.460 |
Why?
|
| Hospices | 4 | 2023 | 32 | 0.460 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 1023 | 0.460 |
Why?
|
| Internet | 2 | 2015 | 458 | 0.460 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 151 | 0.460 |
Why?
|
| Writing | 1 | 2014 | 43 | 0.460 |
Why?
|
| Pressure Ulcer | 2 | 2023 | 35 | 0.450 |
Why?
|
| Rhode Island | 15 | 2016 | 97 | 0.450 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 148 | 0.450 |
Why?
|
| Homosexuality, Female | 1 | 2014 | 21 | 0.450 |
Why?
|
| Physician-Patient Relations | 2 | 2007 | 388 | 0.450 |
Why?
|
| Outpatients | 2 | 2022 | 131 | 0.450 |
Why?
|
| Menarche | 1 | 2013 | 34 | 0.440 |
Why?
|
| Research Personnel | 1 | 2014 | 86 | 0.440 |
Why?
|
| China | 2 | 2024 | 141 | 0.440 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 53 | 0.440 |
Why?
|
| Risk | 6 | 2018 | 372 | 0.440 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 39 | 0.440 |
Why?
|
| Information Dissemination | 2 | 2014 | 117 | 0.440 |
Why?
|
| Intestinal Absorption | 1 | 2013 | 28 | 0.440 |
Why?
|
| Publishing | 1 | 2014 | 90 | 0.440 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 113 | 0.440 |
Why?
|
| Sex Characteristics | 3 | 2020 | 198 | 0.440 |
Why?
|
| Injections, Intra-Articular | 3 | 2018 | 45 | 0.430 |
Why?
|
| Schizophrenia | 3 | 2021 | 256 | 0.430 |
Why?
|
| Preventive Health Services | 2 | 2013 | 72 | 0.430 |
Why?
|
| Evidence-Based Medicine | 5 | 2019 | 452 | 0.430 |
Why?
|
| Drug Interactions | 3 | 2008 | 115 | 0.430 |
Why?
|
| Comprehension | 1 | 2014 | 127 | 0.430 |
Why?
|
| Thiazolidinediones | 2 | 2013 | 52 | 0.430 |
Why?
|
| Multiple Myeloma | 3 | 2023 | 322 | 0.420 |
Why?
|
| Primary Health Care | 3 | 2021 | 647 | 0.420 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2010 | 51 | 0.420 |
Why?
|
| Sexism | 2 | 2024 | 31 | 0.420 |
Why?
|
| Spouse Abuse | 1 | 2013 | 42 | 0.420 |
Why?
|
| Health Status | 11 | 2021 | 449 | 0.420 |
Why?
|
| Videodisc Recording | 1 | 2012 | 8 | 0.420 |
Why?
|
| Women's Health | 5 | 2019 | 390 | 0.420 |
Why?
|
| Arthritis, Psoriatic | 2 | 2023 | 31 | 0.420 |
Why?
|
| Delayed Diagnosis | 3 | 2022 | 43 | 0.420 |
Why?
|
| Administration, Oral | 4 | 2024 | 344 | 0.410 |
Why?
|
| Motor Activity | 1 | 2015 | 343 | 0.410 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 926 | 0.410 |
Why?
|
| Mandatory Programs | 1 | 2012 | 19 | 0.410 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2012 | 24 | 0.410 |
Why?
|
| Palliative Care | 4 | 2020 | 202 | 0.400 |
Why?
|
| Benzodiazepines | 6 | 2020 | 98 | 0.400 |
Why?
|
| Coffee | 1 | 2012 | 19 | 0.400 |
Why?
|
| Decompressive Craniectomy | 1 | 2012 | 5 | 0.400 |
Why?
|
| Drug Therapy, Computer-Assisted | 2 | 2010 | 10 | 0.390 |
Why?
|
| Pregnancy, Unplanned | 1 | 2012 | 22 | 0.390 |
Why?
|
| Caffeine | 1 | 2012 | 47 | 0.390 |
Why?
|
| Interleukin-6 | 1 | 2013 | 309 | 0.390 |
Why?
|
| Abortion, Induced | 1 | 2012 | 24 | 0.390 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 63 | 0.380 |
Why?
|
| Bacteremia | 1 | 2012 | 94 | 0.380 |
Why?
|
| Health Services Research | 7 | 2014 | 270 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 233 | 0.380 |
Why?
|
| Monitoring, Physiologic | 2 | 2017 | 150 | 0.380 |
Why?
|
| Precision Medicine | 1 | 2012 | 103 | 0.380 |
Why?
|
| Coronary Disease | 10 | 2002 | 250 | 0.380 |
Why?
|
| Perception | 2 | 2014 | 179 | 0.380 |
Why?
|
| Skin Neoplasms | 4 | 2011 | 404 | 0.380 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 410 | 0.370 |
Why?
|
| Referral and Consultation | 3 | 2020 | 409 | 0.370 |
Why?
|
| Hemorrhage | 4 | 2024 | 277 | 0.370 |
Why?
|
| Health Education | 1 | 2012 | 184 | 0.370 |
Why?
|
| Public Housing | 1 | 2011 | 11 | 0.370 |
Why?
|
| Antirheumatic Agents | 2 | 2024 | 213 | 0.360 |
Why?
|
| Sexual and Gender Minorities | 2 | 2023 | 73 | 0.360 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 465 | 0.360 |
Why?
|
| Estrogens | 3 | 2019 | 113 | 0.360 |
Why?
|
| Gonorrhea | 1 | 2013 | 196 | 0.360 |
Why?
|
| Transgender Persons | 2 | 2022 | 62 | 0.360 |
Why?
|
| Health Promotion | 2 | 2011 | 491 | 0.360 |
Why?
|
| Communication | 4 | 2017 | 554 | 0.360 |
Why?
|
| Software Validation | 1 | 2010 | 8 | 0.350 |
Why?
|
| Anxiety | 2 | 2023 | 395 | 0.350 |
Why?
|
| Withholding Treatment | 1 | 2010 | 39 | 0.350 |
Why?
|
| Work Schedule Tolerance | 1 | 2010 | 26 | 0.350 |
Why?
|
| Fatigue | 1 | 2011 | 104 | 0.340 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 669 | 0.340 |
Why?
|
| Models, Organizational | 1 | 2010 | 92 | 0.340 |
Why?
|
| Terminal Care | 2 | 2011 | 95 | 0.340 |
Why?
|
| Income | 3 | 2020 | 160 | 0.340 |
Why?
|
| Adolescent Behavior | 1 | 2011 | 188 | 0.340 |
Why?
|
| Norway | 4 | 2017 | 19 | 0.330 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 83 | 0.330 |
Why?
|
| User-Computer Interface | 1 | 2010 | 129 | 0.330 |
Why?
|
| Fathers | 1 | 2009 | 26 | 0.330 |
Why?
|
| Personnel Staffing and Scheduling | 3 | 2006 | 71 | 0.330 |
Why?
|
| Residential Facilities | 1 | 2009 | 18 | 0.330 |
Why?
|
| Prescription Drugs | 2 | 2013 | 50 | 0.330 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 325 | 0.320 |
Why?
|
| Psychometrics | 4 | 2022 | 356 | 0.320 |
Why?
|
| Family | 2 | 2024 | 220 | 0.320 |
Why?
|
| Inpatients | 2 | 2023 | 296 | 0.320 |
Why?
|
| Aspirin | 6 | 2003 | 186 | 0.320 |
Why?
|
| Program Evaluation | 3 | 2010 | 484 | 0.320 |
Why?
|
| Motor Skills | 1 | 2009 | 58 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 809 | 0.310 |
Why?
|
| Depression, Postpartum | 2 | 2023 | 162 | 0.310 |
Why?
|
| Carrier Proteins | 1 | 2013 | 710 | 0.310 |
Why?
|
| Nutrition Surveys | 5 | 2021 | 152 | 0.310 |
Why?
|
| Myocardial Ischemia | 2 | 2002 | 109 | 0.310 |
Why?
|
| Smoking Cessation | 4 | 2020 | 531 | 0.310 |
Why?
|
| Length of Stay | 3 | 2023 | 771 | 0.310 |
Why?
|
| Safety Management | 2 | 2006 | 143 | 0.300 |
Why?
|
| Nootropic Agents | 2 | 2005 | 7 | 0.300 |
Why?
|
| Attitude to Computers | 1 | 2008 | 21 | 0.300 |
Why?
|
| Drug Substitution | 2 | 2019 | 42 | 0.300 |
Why?
|
| Nursing Faculty Practice | 1 | 2008 | 2 | 0.300 |
Why?
|
| Tacrine | 3 | 2005 | 3 | 0.300 |
Why?
|
| Marital Status | 3 | 2018 | 43 | 0.300 |
Why?
|
| Emotions | 2 | 2023 | 217 | 0.300 |
Why?
|
| Patient Transfer | 2 | 2020 | 93 | 0.290 |
Why?
|
| Tramadol | 2 | 2018 | 16 | 0.290 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2007 | 27 | 0.290 |
Why?
|
| Arthritis | 2 | 2013 | 50 | 0.290 |
Why?
|
| Organizational Culture | 6 | 2011 | 112 | 0.290 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1031 | 0.290 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1095 | 0.280 |
Why?
|
| Reminder Systems | 1 | 2008 | 72 | 0.280 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 30 | 0.280 |
Why?
|
| Ketolides | 1 | 2007 | 2 | 0.280 |
Why?
|
| Massachusetts | 11 | 2020 | 2086 | 0.270 |
Why?
|
| Diuretics | 4 | 2003 | 58 | 0.270 |
Why?
|
| Delayed-Action Preparations | 2 | 2018 | 105 | 0.270 |
Why?
|
| Stress, Psychological | 3 | 2011 | 443 | 0.270 |
Why?
|
| Health Care Surveys | 3 | 2019 | 279 | 0.270 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 197 | 0.270 |
Why?
|
| Community Pharmacy Services | 1 | 2006 | 14 | 0.270 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2007 | 41 | 0.270 |
Why?
|
| Patient Admission | 6 | 2021 | 185 | 0.270 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2008 | 167 | 0.270 |
Why?
|
| Pregnancy in Adolescence | 1 | 2006 | 23 | 0.260 |
Why?
|
| Reference Values | 4 | 2020 | 321 | 0.260 |
Why?
|
| Parity | 1 | 2006 | 71 | 0.260 |
Why?
|
| Child, Preschool | 4 | 2016 | 1839 | 0.250 |
Why?
|
| Personality Inventory | 2 | 2015 | 50 | 0.250 |
Why?
|
| Secondary Prevention | 4 | 2018 | 153 | 0.250 |
Why?
|
| Geriatrics | 3 | 2011 | 41 | 0.250 |
Why?
|
| Liver Diseases | 1 | 2007 | 137 | 0.250 |
Why?
|
| Knee | 2 | 2015 | 35 | 0.250 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2014 | 93 | 0.240 |
Why?
|
| Nurses | 1 | 2006 | 103 | 0.240 |
Why?
|
| Hypertension | 8 | 2005 | 601 | 0.240 |
Why?
|
| Weight Loss | 3 | 2014 | 260 | 0.240 |
Why?
|
| Prognosis | 9 | 2019 | 1572 | 0.240 |
Why?
|
| Dietary Fats | 2 | 2017 | 204 | 0.240 |
Why?
|
| Testicular Hormones | 1 | 2004 | 11 | 0.240 |
Why?
|
| Leydig Cells | 1 | 2004 | 12 | 0.240 |
Why?
|
| Virginia | 2 | 2014 | 16 | 0.230 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 384 | 0.230 |
Why?
|
| Liver Transplantation | 2 | 2016 | 189 | 0.230 |
Why?
|
| Private Sector | 1 | 2004 | 14 | 0.230 |
Why?
|
| Burnout, Professional | 1 | 2006 | 122 | 0.230 |
Why?
|
| Public Sector | 1 | 2004 | 19 | 0.230 |
Why?
|
| Acute Coronary Syndrome | 2 | 2019 | 258 | 0.230 |
Why?
|
| Efficiency, Organizational | 1 | 2005 | 95 | 0.230 |
Why?
|
| Interviews as Topic | 5 | 2016 | 486 | 0.230 |
Why?
|
| Life Style | 7 | 2015 | 328 | 0.220 |
Why?
|
| Women's Health Services | 1 | 2004 | 31 | 0.220 |
Why?
|
| Neck Pain | 2 | 2014 | 18 | 0.220 |
Why?
|
| Fever | 1 | 2004 | 63 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2004 | 50 | 0.220 |
Why?
|
| Anxiety Disorders | 2 | 2015 | 188 | 0.220 |
Why?
|
| Hearing Loss | 1 | 2024 | 46 | 0.220 |
Why?
|
| Recurrence | 2 | 2017 | 578 | 0.220 |
Why?
|
| Quality Indicators, Health Care | 5 | 2015 | 328 | 0.220 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 67 | 0.220 |
Why?
|
| Medical Informatics | 2 | 2015 | 68 | 0.220 |
Why?
|
| Glycoproteins | 1 | 2004 | 194 | 0.220 |
Why?
|
| Hysterectomy | 1 | 2004 | 71 | 0.220 |
Why?
|
| Thromboembolism | 2 | 2018 | 70 | 0.210 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 1129 | 0.210 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 421 | 0.210 |
Why?
|
| Norepinephrine | 1 | 2023 | 99 | 0.210 |
Why?
|
| Homocysteine | 6 | 1999 | 57 | 0.210 |
Why?
|
| Life Expectancy | 2 | 2021 | 34 | 0.210 |
Why?
|
| Pain, Postoperative | 2 | 2014 | 129 | 0.200 |
Why?
|
| Mental Health | 3 | 2022 | 348 | 0.200 |
Why?
|
| Cultural Diversity | 2 | 2013 | 52 | 0.200 |
Why?
|
| Independent Living | 1 | 2023 | 45 | 0.200 |
Why?
|
| Leadership | 2 | 2023 | 201 | 0.200 |
Why?
|
| Bulimia Nervosa | 1 | 2022 | 10 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 72 | 0.200 |
Why?
|
| Anorexia Nervosa | 1 | 2022 | 15 | 0.200 |
Why?
|
| Pediatricians | 1 | 2023 | 50 | 0.200 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 69 | 0.200 |
Why?
|
| Telemedicine | 1 | 2007 | 335 | 0.200 |
Why?
|
| Patient Readmission | 2 | 2017 | 420 | 0.200 |
Why?
|
| Insurance | 1 | 2022 | 16 | 0.200 |
Why?
|
| Puerto Rico | 1 | 2023 | 227 | 0.200 |
Why?
|
| Paraproteinemias | 1 | 2022 | 18 | 0.200 |
Why?
|
| Military Personnel | 2 | 2013 | 97 | 0.200 |
Why?
|
| Rheumatology | 1 | 2022 | 65 | 0.200 |
Why?
|
| Registries | 2 | 2017 | 803 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 158 | 0.190 |
Why?
|
| Disability Evaluation | 3 | 2017 | 216 | 0.190 |
Why?
|
| Survival Analysis | 8 | 2017 | 553 | 0.190 |
Why?
|
| Multilevel Analysis | 1 | 2021 | 7 | 0.190 |
Why?
|
| Sports Medicine | 1 | 2021 | 22 | 0.190 |
Why?
|
| Digestive System | 1 | 2001 | 25 | 0.190 |
Why?
|
| General Practitioners | 1 | 2021 | 15 | 0.190 |
Why?
|
| Observational Studies as Topic | 2 | 2019 | 60 | 0.180 |
Why?
|
| Gastrointestinal Agents | 1 | 2001 | 29 | 0.180 |
Why?
|
| Glasgow Outcome Scale | 2 | 2011 | 17 | 0.180 |
Why?
|
| Attitude to Health | 3 | 2012 | 275 | 0.180 |
Why?
|
| Delphi Technique | 1 | 2021 | 82 | 0.180 |
Why?
|
| Ownership | 4 | 2013 | 17 | 0.180 |
Why?
|
| Geriatric Nursing | 2 | 2011 | 49 | 0.180 |
Why?
|
| Maternal Exposure | 2 | 2017 | 40 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 13 | 0.180 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2020 | 24 | 0.180 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2000 | 86 | 0.180 |
Why?
|
| Assisted Living Facilities | 2 | 2017 | 10 | 0.170 |
Why?
|
| Neuromuscular Agents | 1 | 2020 | 18 | 0.170 |
Why?
|
| Pruritus | 1 | 2020 | 29 | 0.170 |
Why?
|
| Tretinoin | 2 | 2011 | 48 | 0.170 |
Why?
|
| Analgesia | 1 | 2020 | 32 | 0.170 |
Why?
|
| Acculturation | 1 | 2020 | 47 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 337 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 114 | 0.170 |
Why?
|
| Endometrial Hyperplasia | 1 | 2019 | 2 | 0.170 |
Why?
|
| Suicide | 1 | 2021 | 123 | 0.170 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 79 | 0.170 |
Why?
|
| Social Environment | 1 | 2020 | 95 | 0.170 |
Why?
|
| Psychomotor Agitation | 2 | 2017 | 19 | 0.170 |
Why?
|
| Religion | 1 | 2019 | 33 | 0.160 |
Why?
|
| Perinatal Care | 1 | 2020 | 61 | 0.160 |
Why?
|
| Educational Measurement | 1 | 2021 | 207 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 90 | 0.160 |
Why?
|
| Oral Health | 1 | 2020 | 75 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 43 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2019 | 11 | 0.160 |
Why?
|
| Clinical Competence | 3 | 2017 | 678 | 0.160 |
Why?
|
| Decision Making | 3 | 2016 | 390 | 0.160 |
Why?
|
| Medically Uninsured | 2 | 2012 | 40 | 0.160 |
Why?
|
| North Carolina | 2 | 2010 | 66 | 0.160 |
Why?
|
| Weight Gain | 2 | 2010 | 161 | 0.160 |
Why?
|
| Firearms | 1 | 2020 | 60 | 0.160 |
Why?
|
| Probability | 1 | 2019 | 172 | 0.160 |
Why?
|
| Health Services for the Aged | 3 | 2007 | 48 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 442 | 0.150 |
Why?
|
| Renal Dialysis | 5 | 1999 | 185 | 0.150 |
Why?
|
| Patient Selection | 2 | 2015 | 446 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 60 | 0.150 |
Why?
|
| Neuropsychological Tests | 5 | 2015 | 340 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2009 | 61 | 0.150 |
Why?
|
| Sleep | 1 | 2021 | 219 | 0.150 |
Why?
|
| Cartilage, Articular | 1 | 2018 | 74 | 0.150 |
Why?
|
| Residential Treatment | 1 | 2018 | 35 | 0.150 |
Why?
|
| Students, Medical | 1 | 2021 | 243 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 100 | 0.150 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 282 | 0.140 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 10 | 0.140 |
Why?
|
| Anhedonia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Deficiency Diseases | 1 | 2017 | 12 | 0.140 |
Why?
|
| New Hampshire | 1 | 2017 | 42 | 0.140 |
Why?
|
| Iodine | 1 | 2017 | 21 | 0.140 |
Why?
|
| Medical Staff | 1 | 2017 | 14 | 0.140 |
Why?
|
| Ischemia | 1 | 1999 | 192 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1134 | 0.140 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2018 | 103 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2017 | 29 | 0.140 |
Why?
|
| Personnel Turnover | 2 | 2007 | 21 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 261 | 0.140 |
Why?
|
| Half-Life | 2 | 2015 | 70 | 0.140 |
Why?
|
| Home Care Services | 1 | 2018 | 103 | 0.140 |
Why?
|
| Inservice Training | 1 | 2017 | 83 | 0.140 |
Why?
|
| Oxymorphone | 1 | 2016 | 6 | 0.140 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 27 | 0.140 |
Why?
|
| Menopause | 1 | 2019 | 246 | 0.130 |
Why?
|
| Professional Autonomy | 2 | 2006 | 21 | 0.130 |
Why?
|
| Infant | 2 | 2022 | 1527 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2016 | 21 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 160 | 0.130 |
Why?
|
| Focus Groups | 2 | 2008 | 291 | 0.130 |
Why?
|
| Hepatitis C | 1 | 1998 | 139 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 85 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2016 | 48 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 5 | 2009 | 72 | 0.130 |
Why?
|
| Risk Reduction Behavior | 3 | 2017 | 125 | 0.130 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2015 | 5 | 0.130 |
Why?
|
| Internal-External Control | 1 | 2015 | 32 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 159 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2010 | 919 | 0.130 |
Why?
|
| Patients | 1 | 2017 | 102 | 0.130 |
Why?
|
| Men's Health | 1 | 2015 | 11 | 0.130 |
Why?
|
| Phobic Disorders | 1 | 2015 | 15 | 0.130 |
Why?
|
| Opiate Substitution Treatment | 1 | 2018 | 192 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 79 | 0.130 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 87 | 0.130 |
Why?
|
| Paliperidone Palmitate | 1 | 2015 | 1 | 0.130 |
Why?
|
| Drug Combinations | 2 | 2015 | 140 | 0.130 |
Why?
|
| Workload | 2 | 2006 | 121 | 0.130 |
Why?
|
| Accelerometry | 1 | 2016 | 59 | 0.130 |
Why?
|
| Musculoskeletal Pain | 1 | 2015 | 28 | 0.120 |
Why?
|
| Affect | 5 | 2009 | 121 | 0.120 |
Why?
|
| Health Policy | 2 | 2016 | 185 | 0.120 |
Why?
|
| Infertility, Female | 1 | 1995 | 46 | 0.120 |
Why?
|
| Ohio | 2 | 2006 | 26 | 0.120 |
Why?
|
| Child Behavior Disorders | 1 | 2015 | 42 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 220 | 0.120 |
Why?
|
| Femoral Fractures | 3 | 2007 | 21 | 0.120 |
Why?
|
| Nurse's Role | 2 | 2006 | 121 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 314 | 0.120 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 35 | 0.120 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 403 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 4 | 2008 | 31 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 46 | 0.120 |
Why?
|
| Biomarkers | 4 | 2022 | 1210 | 0.120 |
Why?
|
| Insurance Claim Reporting | 2 | 2006 | 18 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2012 | 250 | 0.120 |
Why?
|
| Community Mental Health Centers | 1 | 2014 | 18 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2015 | 68 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2014 | 46 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 277 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 143 | 0.110 |
Why?
|
| Milk | 1 | 2014 | 50 | 0.110 |
Why?
|
| Femur | 1 | 2014 | 54 | 0.110 |
Why?
|
| Interpersonal Relations | 2 | 2013 | 150 | 0.110 |
Why?
|
| Manipulation, Orthopedic | 1 | 2013 | 6 | 0.110 |
Why?
|
| Manipulation, Chiropractic | 1 | 2013 | 5 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 45 | 0.110 |
Why?
|
| Tibia | 1 | 2014 | 70 | 0.110 |
Why?
|
| Metronidazole | 1 | 2013 | 7 | 0.110 |
Why?
|
| Fatty Acids | 1 | 1995 | 194 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 214 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 68 | 0.110 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 11 | 0.110 |
Why?
|
| Medical History Taking | 2 | 2017 | 58 | 0.110 |
Why?
|
| Prenatal Care | 2 | 2020 | 180 | 0.110 |
Why?
|
| Drug Monitoring | 2 | 2011 | 99 | 0.110 |
Why?
|
| Constipation | 1 | 2013 | 16 | 0.110 |
Why?
|
| Cannabinoids | 1 | 2013 | 35 | 0.110 |
Why?
|
| Baltimore | 1 | 2013 | 18 | 0.110 |
Why?
|
| Sepsis | 1 | 2017 | 281 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 104 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2017 | 449 | 0.110 |
Why?
|
| Osteoporosis | 2 | 2006 | 137 | 0.110 |
Why?
|
| Single-Blind Method | 2 | 2011 | 133 | 0.110 |
Why?
|
| Gastric Acid | 1 | 2012 | 10 | 0.100 |
Why?
|
| Arthralgia | 1 | 2013 | 59 | 0.100 |
Why?
|
| Cause of Death | 3 | 2019 | 200 | 0.100 |
Why?
|
| Pediatric Obesity | 1 | 2014 | 93 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2012 | 11 | 0.100 |
Why?
|
| Buprenorphine | 1 | 2016 | 186 | 0.100 |
Why?
|
| Health Facilities, Proprietary | 2 | 2013 | 4 | 0.100 |
Why?
|
| Housing | 1 | 2013 | 72 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 355 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 173 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2014 | 161 | 0.100 |
Why?
|
| Schistosoma japonicum | 1 | 2012 | 1 | 0.100 |
Why?
|
| Schistosomiasis japonica | 1 | 2012 | 1 | 0.100 |
Why?
|
| Praziquantel | 1 | 2012 | 2 | 0.100 |
Why?
|
| Parasite Load | 1 | 2012 | 3 | 0.100 |
Why?
|
| Metformin | 1 | 2013 | 67 | 0.100 |
Why?
|
| Economic Competition | 2 | 2013 | 8 | 0.100 |
Why?
|
| Nausea | 1 | 2013 | 109 | 0.100 |
Why?
|
| Survival Rate | 4 | 2019 | 791 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2017 | 846 | 0.100 |
Why?
|
| State Government | 1 | 2012 | 32 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 21 | 0.100 |
Why?
|
| Keratinocytes | 2 | 2011 | 63 | 0.100 |
Why?
|
| Simvastatin | 1 | 2012 | 28 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2013 | 513 | 0.100 |
Why?
|
| Hospitals, Veterans | 1 | 2013 | 159 | 0.100 |
Why?
|
| Vomiting | 1 | 2013 | 134 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 50 | 0.100 |
Why?
|
| Empirical Research | 1 | 2011 | 14 | 0.100 |
Why?
|
| Drug Therapy, Combination | 6 | 2003 | 436 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2012 | 98 | 0.100 |
Why?
|
| Workplace | 2 | 2006 | 180 | 0.100 |
Why?
|
| Anthelmintics | 1 | 2012 | 42 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 139 | 0.100 |
Why?
|
| Physical Examination | 2 | 2022 | 103 | 0.090 |
Why?
|
| Software Design | 1 | 2011 | 28 | 0.090 |
Why?
|
| Linear Models | 3 | 2017 | 422 | 0.090 |
Why?
|
| Pain, Intractable | 1 | 2011 | 4 | 0.090 |
Why?
|
| Pharmacies | 1 | 2011 | 36 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 46 | 0.090 |
Why?
|
| Censuses | 1 | 2010 | 14 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 365 | 0.090 |
Why?
|
| Peer Group | 1 | 2011 | 95 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 237 | 0.090 |
Why?
|
| Personal Satisfaction | 1 | 2011 | 77 | 0.090 |
Why?
|
| Tranquilizing Agents | 1 | 2010 | 2 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 117 | 0.090 |
Why?
|
| Antiparkinson Agents | 1 | 2010 | 9 | 0.090 |
Why?
|
| Parents | 1 | 2014 | 379 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 446 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 10 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 34 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2022 | 155 | 0.090 |
Why?
|
| Northern Ireland | 1 | 2009 | 1 | 0.090 |
Why?
|
| Digoxin | 2 | 2000 | 17 | 0.090 |
Why?
|
| Nursing Administration Research | 2 | 2008 | 8 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 3 | 1996 | 193 | 0.090 |
Why?
|
| Parkinsonian Disorders | 1 | 2009 | 13 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2002 | 252 | 0.080 |
Why?
|
| Dementia, Vascular | 2 | 1999 | 8 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 98 | 0.080 |
Why?
|
| United Kingdom | 2 | 2007 | 69 | 0.080 |
Why?
|
| Behavior | 1 | 2009 | 38 | 0.080 |
Why?
|
| Specialties, Nursing | 1 | 2008 | 7 | 0.080 |
Why?
|
| Self Administration | 1 | 2008 | 47 | 0.080 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 27 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 26 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 341 | 0.080 |
Why?
|
| Vaginosis, Bacterial | 1 | 2008 | 13 | 0.080 |
Why?
|
| Voluntary Health Agencies | 1 | 2008 | 4 | 0.080 |
Why?
|
| Home Care Agencies | 1 | 2008 | 5 | 0.070 |
Why?
|
| Physician Assistants | 1 | 2008 | 37 | 0.070 |
Why?
|
| Walking | 2 | 2020 | 229 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 2 | 2001 | 87 | 0.070 |
Why?
|
| Postal Service | 1 | 2007 | 6 | 0.070 |
Why?
|
| Databases as Topic | 4 | 2002 | 53 | 0.070 |
Why?
|
| Unsafe Sex | 1 | 2007 | 27 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 23 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2008 | 75 | 0.070 |
Why?
|
| Protective Factors | 2 | 2017 | 34 | 0.070 |
Why?
|
| Government Regulation | 1 | 2007 | 44 | 0.070 |
Why?
|
| New York | 3 | 2002 | 136 | 0.070 |
Why?
|
| Nurse Practitioners | 1 | 2008 | 115 | 0.070 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2004 | 20 | 0.070 |
Why?
|
| Physical Fitness | 2 | 1999 | 92 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2006 | 83 | 0.070 |
Why?
|
| Contraceptives, Oral | 2 | 1996 | 25 | 0.070 |
Why?
|
| Bed Occupancy | 1 | 2006 | 13 | 0.070 |
Why?
|
| Health Facility Size | 1 | 2006 | 17 | 0.070 |
Why?
|
| HIV Infections | 1 | 2013 | 921 | 0.070 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2006 | 36 | 0.070 |
Why?
|
| Animals | 4 | 2014 | 19647 | 0.060 |
Why?
|
| Certification | 1 | 2006 | 49 | 0.060 |
Why?
|
| Personal Health Services | 1 | 2005 | 1 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 131 | 0.060 |
Why?
|
| Nursing Assessment | 1 | 2005 | 41 | 0.060 |
Why?
|
| Dipyridamole | 2 | 2003 | 17 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2006 | 201 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2005 | 49 | 0.060 |
Why?
|
| South Dakota | 2 | 2002 | 5 | 0.060 |
Why?
|
| Maine | 2 | 2002 | 16 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 107 | 0.060 |
Why?
|
| Veterans | 1 | 2012 | 723 | 0.060 |
Why?
|
| Nurse Administrators | 1 | 2024 | 19 | 0.060 |
Why?
|
| Perimenopause | 1 | 2004 | 31 | 0.060 |
Why?
|
| Ticlopidine | 2 | 2003 | 66 | 0.060 |
Why?
|
| Organ Size | 1 | 2004 | 161 | 0.060 |
Why?
|
| Sexual Maturation | 1 | 2004 | 50 | 0.060 |
Why?
|
| New England | 7 | 2000 | 268 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2004 | 56 | 0.060 |
Why?
|
| Population Health | 1 | 2024 | 15 | 0.060 |
Why?
|
| Testosterone | 1 | 2004 | 111 | 0.060 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2004 | 62 | 0.060 |
Why?
|
| Medical Assistance | 1 | 2004 | 10 | 0.060 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2004 | 11 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 142 | 0.060 |
Why?
|
| Testis | 1 | 2004 | 136 | 0.060 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 101 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 138 | 0.050 |
Why?
|
| Chromosomes, Human, Y | 1 | 2003 | 5 | 0.050 |
Why?
|
| Prejudice | 1 | 2003 | 61 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 216 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 645 | 0.050 |
Why?
|
| Suppuration | 1 | 2023 | 11 | 0.050 |
Why?
|
| Ulcer | 1 | 2023 | 15 | 0.050 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 127 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2003 | 77 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2004 | 188 | 0.050 |
Why?
|
| Thiocyanates | 1 | 2002 | 7 | 0.050 |
Why?
|
| Cotinine | 1 | 2002 | 18 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2004 | 175 | 0.050 |
Why?
|
| Research | 1 | 2004 | 191 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2005 | 158 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 94 | 0.050 |
Why?
|
| Health Status Indicators | 2 | 2016 | 98 | 0.050 |
Why?
|
| Cholesterol | 4 | 1999 | 255 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2002 | 54 | 0.050 |
Why?
|
| Pneumonia, Aspiration | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cholesterol, HDL | 3 | 1997 | 78 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2002 | 21 | 0.050 |
Why?
|
| Calcium Channel Blockers | 2 | 1999 | 56 | 0.050 |
Why?
|
| Sensation Disorders | 1 | 2002 | 21 | 0.050 |
Why?
|
| Economics, Hospital | 1 | 2002 | 14 | 0.050 |
Why?
|
| Regression Analysis | 4 | 2007 | 484 | 0.050 |
Why?
|
| Minnesota | 1 | 2001 | 37 | 0.050 |
Why?
|
| Hypercholesterolemia | 2 | 1999 | 68 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 299 | 0.050 |
Why?
|
| Facility Regulation and Control | 1 | 2000 | 3 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 254 | 0.040 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2020 | 14 | 0.040 |
Why?
|
| Oregon | 1 | 2020 | 19 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 2001 | 93 | 0.040 |
Why?
|
| Home Nursing | 1 | 2000 | 21 | 0.040 |
Why?
|
| Social Behavior Disorders | 1 | 2000 | 6 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2000 | 59 | 0.040 |
Why?
|
| Walking Speed | 1 | 2020 | 21 | 0.040 |
Why?
|
| Spouses | 1 | 2020 | 38 | 0.040 |
Why?
|
| Administration, Topical | 2 | 2011 | 52 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 100 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2104 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2000 | 48 | 0.040 |
Why?
|
| Postnatal Care | 1 | 2020 | 41 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 11 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 108 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 88 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2019 | 25 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1989 | 0.040 |
Why?
|
| Nitrates | 1 | 1999 | 20 | 0.040 |
Why?
|
| Gait | 1 | 2020 | 114 | 0.040 |
Why?
|
| Vitamin B Complex | 2 | 1996 | 22 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1470 | 0.040 |
Why?
|
| Occupational Health Services | 1 | 1999 | 39 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1999 | 63 | 0.040 |
Why?
|
| Office Visits | 1 | 1999 | 41 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 376 | 0.040 |
Why?
|
| Survivors | 1 | 2019 | 148 | 0.040 |
Why?
|
| Body Height | 1 | 1998 | 75 | 0.040 |
Why?
|
| Syncope | 1 | 2018 | 42 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 387 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2011 | 680 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1998 | 37 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 99 | 0.040 |
Why?
|
| Fetal Development | 1 | 2017 | 17 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 7 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2017 | 13 | 0.040 |
Why?
|
| Classification | 1 | 2017 | 12 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3194 | 0.040 |
Why?
|
| Hospital Departments | 1 | 2017 | 13 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 75 | 0.040 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 17 | 0.040 |
Why?
|
| Alberta | 1 | 2017 | 4 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 1998 | 148 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 1999 | 266 | 0.030 |
Why?
|
| Social Behavior | 2 | 2009 | 88 | 0.030 |
Why?
|
| Thrombosis | 1 | 1999 | 195 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2016 | 9 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2017 | 53 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1996 | 8 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 108 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 58 | 0.030 |
Why?
|
| Behavior Control | 1 | 2016 | 15 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 112 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 145 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 1996 | 2 | 0.030 |
Why?
|
| Self Disclosure | 1 | 1996 | 37 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 1996 | 12 | 0.030 |
Why?
|
| Fibrinogen | 1 | 1996 | 38 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2012 | 305 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 51 | 0.030 |
Why?
|
| Diet Surveys | 1 | 1996 | 77 | 0.030 |
Why?
|
| Folic Acid | 1 | 1996 | 58 | 0.030 |
Why?
|
| Quality Control | 2 | 2010 | 70 | 0.030 |
Why?
|
| Urban Health | 1 | 2015 | 43 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 302 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 79 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 68 | 0.030 |
Why?
|
| Restraint, Physical | 2 | 2008 | 31 | 0.030 |
Why?
|
| Diet, Diabetic | 1 | 1995 | 11 | 0.030 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1995 | 27 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 104 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 21 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 43 | 0.030 |
Why?
|
| Demography | 2 | 2007 | 178 | 0.030 |
Why?
|
| Diet | 2 | 1995 | 635 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 410 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 2039 | 0.030 |
Why?
|
| Trichuris | 1 | 2012 | 8 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2005 | 66 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2012 | 50 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 576 | 0.020 |
Why?
|
| Ireland | 1 | 2011 | 17 | 0.020 |
Why?
|
| Schools | 1 | 2012 | 156 | 0.020 |
Why?
|
| Mice | 1 | 2004 | 10266 | 0.020 |
Why?
|
| Morbidity | 2 | 2000 | 109 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 201 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 28 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2009 | 37 | 0.020 |
Why?
|
| Ear Neoplasms | 1 | 2009 | 6 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 2009 | 7 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 154 | 0.020 |
Why?
|
| Aggression | 1 | 2009 | 57 | 0.020 |
Why?
|
| Blood Pressure | 3 | 1996 | 522 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 2008 | 71 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2009 | 137 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 56 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 18 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2007 | 25 | 0.020 |
Why?
|
| Condoms | 1 | 2007 | 47 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 900 | 0.020 |
Why?
|
| Heart Diseases | 2 | 2000 | 204 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 301 | 0.020 |
Why?
|
| Narcotics | 1 | 2006 | 50 | 0.020 |
Why?
|
| Arteriosclerosis | 2 | 1996 | 30 | 0.020 |
Why?
|
| Clozapine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2005 | 73 | 0.020 |
Why?
|
| Interdepartmental Relations | 1 | 2004 | 1 | 0.010 |
Why?
|
| Decision Making, Organizational | 1 | 2004 | 26 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2004 | 77 | 0.010 |
Why?
|
| Sex Offenses | 1 | 2004 | 46 | 0.010 |
Why?
|
| Population | 1 | 2003 | 13 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 2003 | 18 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 2003 | 25 | 0.010 |
Why?
|
| Child Abuse | 1 | 2004 | 87 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2005 | 170 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 44 | 0.010 |
Why?
|
| Mississippi | 1 | 2002 | 33 | 0.010 |
Why?
|
| Diphosphonates | 1 | 2002 | 35 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 1489 | 0.010 |
Why?
|
| Public Policy | 1 | 2001 | 41 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 2001 | 75 | 0.010 |
Why?
|
| Iceland | 1 | 2000 | 8 | 0.010 |
Why?
|
| Denmark | 1 | 2000 | 22 | 0.010 |
Why?
|
| Sweden | 1 | 2000 | 42 | 0.010 |
Why?
|
| Japan | 1 | 2000 | 57 | 0.010 |
Why?
|
| Italy | 1 | 2000 | 62 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 2000 | 8 | 0.010 |
Why?
|
| Regional Medical Programs | 1 | 2000 | 6 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2000 | 42 | 0.010 |
Why?
|
| Biotransformation | 1 | 2000 | 20 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2000 | 42 | 0.010 |
Why?
|
| Autopsy | 1 | 2000 | 47 | 0.010 |
Why?
|
| Hallucinations | 1 | 2000 | 16 | 0.010 |
Why?
|
| Confusion | 1 | 2000 | 15 | 0.010 |
Why?
|
| Methionine | 1 | 1999 | 56 | 0.010 |
Why?
|
| Diagnosis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 555 | 0.010 |
Why?
|
| Information Systems | 1 | 1999 | 30 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 1999 | 50 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 208 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2000 | 524 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1997 | 66 | 0.010 |
Why?
|
| Epidemiologic Factors | 1 | 1996 | 5 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1998 | 262 | 0.010 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 1996 | 11 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1996 | 28 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1996 | 21 | 0.010 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 1996 | 18 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 1996 | 25 | 0.010 |
Why?
|
| Creatinine | 1 | 1996 | 123 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 195 | 0.010 |
Why?
|
| Colorado | 1 | 1995 | 19 | 0.010 |
Why?
|
| Embolism, Cholesterol | 1 | 1995 | 2 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 1996 | 88 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1995 | 34 | 0.010 |
Why?
|
| Serine | 1 | 1995 | 83 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1995 | 60 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1996 | 159 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1995 | 202 | 0.010 |
Why?
|
| Mental Recall | 1 | 1994 | 94 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1993 | 58 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1993 | 20 | 0.010 |
Why?
|
| Exercise Test | 1 | 1995 | 234 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1582 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 1462 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 659 | 0.010 |
Why?
|